Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1994 2
1995 1
1996 1
2013 2
2014 5
2015 3
2016 1
2017 1
2019 1
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABAB receptor, and morphine in recreational opioid users.
Ito M, Walzer M, Blauwet MB, Spence A, Heo N, Kelsh D, Blahunka P, Erdman J, Alsharif MN, Marek GJ. Ito M, et al. Among authors: blauwet mb. J Psychopharmacol. 2023 May;37(5):449-461. doi: 10.1177/02698811231167852. Epub 2023 Apr 26. J Psychopharmacol. 2023. PMID: 37125424 Clinical Trial.
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD; mirabegron PMR-PASS study group. Hoffman V, et al. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8. Drug Saf. 2021. PMID: 34236595 Free PMC article.
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.
Chapple C, Khullar V, Nitti VW, Frankel J, Herschorn S, Kaper M, Blauwet MB, Siddiqui E. Chapple C, et al. Among authors: blauwet mb. Eur Urol. 2015 Jan;67(1):11-14. doi: 10.1016/j.eururo.2014.06.052. Epub 2014 Aug 2. Eur Urol. 2015. PMID: 25092537 Clinical Trial.
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.
Castro-Diaz D, Chapple CR, Hakimi Z, Blauwet MB, Delgado-Herrera L, Lau W, Mujais S. Castro-Diaz D, et al. Among authors: blauwet mb. Qual Life Res. 2015 Jul;24(7):1719-27. doi: 10.1007/s11136-014-0904-4. Epub 2015 Feb 17. Qual Life Res. 2015. PMID: 25688038 Free PMC article. Clinical Trial.
22 results